ROIV vs. ELAN, CTLT, LEGN, VKTX, CERE, ASND, JAZZ, ITCI, RDY, and BPMC
Should you be buying Roivant Sciences stock or one of its competitors? The main competitors of Roivant Sciences include Elanco Animal Health (ELAN), Catalent (CTLT), Legend Biotech (LEGN), Viking Therapeutics (VKTX), Cerevel Therapeutics (CERE), Ascendis Pharma A/S (ASND), Jazz Pharmaceuticals (JAZZ), Intra-Cellular Therapies (ITCI), Dr. Reddy's Laboratories (RDY), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical preparations" industry.
Roivant Sciences (NASDAQ:ROIV) and Elanco Animal Health (NYSE:ELAN) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, community ranking, media sentiment, dividends, risk, profitability and institutional ownership.
64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are held by institutional investors. 4.6% of Roivant Sciences shares are held by insiders. Comparatively, 0.6% of Elanco Animal Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Elanco Animal Health received 89 more outperform votes than Roivant Sciences when rated by MarketBeat users. However, 75.00% of users gave Roivant Sciences an outperform vote while only 54.13% of users gave Elanco Animal Health an outperform vote.
Roivant Sciences has a beta of 1.3, suggesting that its share price is 30% more volatile than the S&P 500. Comparatively, Elanco Animal Health has a beta of 1.34, suggesting that its share price is 34% more volatile than the S&P 500.
Roivant Sciences has a net margin of 3,624.14% compared to Elanco Animal Health's net margin of -29.83%. Elanco Animal Health's return on equity of 5.98% beat Roivant Sciences' return on equity.
In the previous week, Elanco Animal Health had 6 more articles in the media than Roivant Sciences. MarketBeat recorded 9 mentions for Elanco Animal Health and 3 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.94 beat Elanco Animal Health's score of -0.01 indicating that Roivant Sciences is being referred to more favorably in the media.
Roivant Sciences currently has a consensus price target of $16.90, indicating a potential upside of 50.49%. Elanco Animal Health has a consensus price target of $18.29, indicating a potential upside of 6.37%. Given Roivant Sciences' stronger consensus rating and higher possible upside, research analysts plainly believe Roivant Sciences is more favorable than Elanco Animal Health.
Roivant Sciences has higher earnings, but lower revenue than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks.
Summary
Roivant Sciences beats Elanco Animal Health on 11 of the 18 factors compared between the two stocks.
Get Roivant Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ROIV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ROIV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Roivant Sciences Competitors List
Related Companies and Tools
